Roche announces EMA committee recommends EU label update for its Phesgo to allow administration outside of clinical settings: Basel Friday, May 2, 2025, 12:00 Hrs [IST] Roche anno ...

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody ...

Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

CuraTeQ Biologics (a wholly owned step-down subsidiary of Aurobindo Pharma Limited) announced that its trastuzumab biosimilar, ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

UNIVERSITY OF BATH PRESS RELEASERevolutionary tech promises to transform life-saving antibody treatments and reduce hospital staysWorld Immunisation Week 2025 (24 to 30 April): University of Bath ...

Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was ...